These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

108 related articles for article (PubMed ID: 2771995)

  • 21. [Chemotherapy of bladder tumors].
    Botto H
    Rev Prat; 1994 Feb; 44(4):514-9. PubMed ID: 8184271
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Comparison of BCG with other intravesical agents.
    Lamm DL
    Urology; 1991; 37(5 Suppl):30-2. PubMed ID: 1826979
    [No Abstract]   [Full Text] [Related]  

  • 23. Arthritis and iritis after BCG therapy for bladder cancer.
    Price GE
    J Rheumatol; 1994 Mar; 21(3):564-5. PubMed ID: 8006904
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Editorial comment on: Long-term intravesical adjuvant chemotherapy further reduces recurrence rate compared with short-term intravesical chemotherapy and short-term therapy with Bacillus Calmette-Guérin (BCG) in patients with non-muscle-invasive bladder cancer.
    Evans CP
    Eur Urol; 2007 Oct; 52(4):1129-30. PubMed ID: 17383082
    [No Abstract]   [Full Text] [Related]  

  • 25. The optimal management of T1G3 bladder cancer.
    Emiliozzi P; Pansadoro A; Pansadoro V
    BJU Int; 2008 Nov; 102(9 Pt B):1265-73. PubMed ID: 19035891
    [No Abstract]   [Full Text] [Related]  

  • 26. Vesicorenal reflux and intravesical chemotherapy.
    Mazeman E; Gilliot P
    Prog Clin Biol Res; 1989; 303():517-22. PubMed ID: 2675008
    [No Abstract]   [Full Text] [Related]  

  • 27. [Microdoses of BCG vaccine in the treatment of cancer].
    Rivera P; Caffarena E; Cornejo H; Fonerón A; Haemersli J; del Pino M; Sepúlveda M; Ubilla A
    Rev Med Chil; 1992 Jun; 120(6):700-1. PubMed ID: 1341807
    [No Abstract]   [Full Text] [Related]  

  • 28. Intravesical therapy for superficial bladder cancer.
    Malkowicz SB
    Semin Urol Oncol; 2000 Nov; 18(4):280-8. PubMed ID: 11101091
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Aspects of non-specific immunotherapy with BCG in superficial bladder cancer: an overview.
    van der Meijden AP; Debruyne FM; Steerenberg PA; de Jong WH
    Prog Clin Biol Res; 1989; 310():11-33. PubMed ID: 2672011
    [No Abstract]   [Full Text] [Related]  

  • 30. [Conservative treatment of bladder tumors].
    J Urol (Paris); 1985; 91(10):668-89. PubMed ID: 3842975
    [No Abstract]   [Full Text] [Related]  

  • 31. [A rare complication of antineoplastic BCG therapy: pulmonary tuberculosis].
    Fenniche S; Hasséne H; Attia S; Fkih L; Bousnina S; Cheikh K; Belhabib D; Megdiche ML
    Tunis Med; 2001; 79(8-9):467-70. PubMed ID: 11774792
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Risk-adapted use of intravesical chemotherapy.
    Lerner SP; Au JL
    BJU Int; 2008 Nov; 102(9 Pt B):1247-53. PubMed ID: 19035889
    [No Abstract]   [Full Text] [Related]  

  • 33. [Place of endovesical "BCG Therapy" in superficial tumors of the bladder].
    Zerbib M
    J Urol (Paris); 1995; 101(2):59-63. PubMed ID: 8522855
    [TBL] [Abstract][Full Text] [Related]  

  • 34. BCG therapy for superficial bladder cancer: fundamental aspects.
    Hudson ML; Ratliff TL
    In Vivo; 1991; 5(6):643-6. PubMed ID: 1810450
    [No Abstract]   [Full Text] [Related]  

  • 35. BCG-RIVM intravesical immunoprophylaxis for superficial bladder cancer.
    Debruyne FM; van der Meijden AP; Schreinemachers LM; Geboers AD; Franssen MP; van Leeuwen MJ; Steerenberg PA; de Jong WH; Ruitenberg EJ
    Prog Clin Biol Res; 1988; 269():511-24. PubMed ID: 3134662
    [No Abstract]   [Full Text] [Related]  

  • 36. Intravesical and intradermal BCG-RIVM application: a toxicity study.
    Debruyne FM; van der Meijden AP; Schreinemachers LM; Wagenaar J; Feitz WF; Hendriks B; de Jong WH; Steeren-Berg PA
    Prog Clin Biol Res; 1985; 185B():151-9. PubMed ID: 4034587
    [No Abstract]   [Full Text] [Related]  

  • 37. BCG in the treatment of bladder cancer: state of the art.
    Morales A
    Prog Clin Biol Res; 1989; 310():3-10. PubMed ID: 2672017
    [No Abstract]   [Full Text] [Related]  

  • 38. [A comparative study of BCG and mitomycin C in superficial carcinomas of the bladder].
    Iavarone C; Minocchi L; Arecchi S; Nicolucci D; Porcelli C; D'orazi V; Greco L; Stio F; Martino G; Messinetti S
    G Chir; 1996 May; 17(5):289-91. PubMed ID: 8755233
    [No Abstract]   [Full Text] [Related]  

  • 39. Efficacy and safety of bacille Calmette-Guérin immunotherapy in superficial bladder cancer.
    Lamm DL
    Clin Infect Dis; 2000 Sep; 31 Suppl 3():S86-90. PubMed ID: 11010830
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Treatment and follow-up of superficial bladder cancer].
    Raitanen M
    Duodecim; 2002; 118(9):903-9. PubMed ID: 12238168
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.